Modern pharmaceutical company begins human trials against HIV

The International AIDS Vaccine Initiative is also accompanying this first phase of the process, which will be carried out in 56 American adults without the virus.

mRNA technology raises hope in this trial given the success it has had in developing coronavirus vaccines. Photo: shutterstock.

The start of human trials against a vaccine against human immunodeficiency virusby modern medicineswhich has biotechnology from RNA رسول messengerWhich is used in its vaccines against Covid-19.

The application of mRNA technology raises hope in the midst of this experiment given the success it has had in developing vaccines for the Corona virus.

“By using mRNA to develop drugs, we take advantage of natural biological processes to create the desired therapeutic effect. This gives us the ability to treat a wide range of diseases, many of which cannot be treated with current therapies,” the laboratory states on its website.

This will be the first such immune system used to combat HIV after several decades of research, so volunteers are expected to have a positive response and it will be possible to start implementing it around the world to save lives. thousands. of people.

The scientists’ goal is to stimulate the immune system so that the body’s B cells produce antibodies to bnAb that can work against different types of this virus.

“Induction of bnAbs is widely considered a target for vaccination against human immunodeficiency virusThis is the first step in this process,” Moderna Lab said in a press release.

If the volunteers respond as expected against the causative virus lozengesthe researchers are considering the use of a booster that would allow the vaccine to be boosted further.

These first experimental doses were applied at the George Washington University (GWU) School of Medicine and Health Sciences in Washington, DC, in collaboration with IAVI, the Bill & Melinda Gates Foundation, and the nonprofit Scientific Research Organization.

“We are very pleased to be partnering with IAVI and the Bill & Melinda Gates Foundation to apply our mRNA technology in an environmentally friendly environment. human immunodeficiency virus. “At Moderna, we believe mRNA provides a unique opportunity to address unmet public health needs around the world,” said Stephen Hogg, President of Moderna.

Meanwhile, the health status of people who received biological therapy and the immune system’s response to this important medical advance against the deadly disease are being evaluated.

Source consult here.